erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.

[1]  N. Lemoine,et al.  Antisense technology for cancer therapy: does it make sense? , 1993, British Journal of Cancer.

[2]  G. Canti,et al.  Oligonucleotide degradation contributes to resistance to antisense compounds. , 1993, Anti-cancer drugs.

[3]  R. Lupu,et al.  A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[4]  B. Calabretta,et al.  Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. , 1991, Science.

[5]  M. Colombo,et al.  Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. , 1991, Cancer research.

[6]  A. Ullrich,et al.  Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.

[7]  B. Tocqué,et al.  Short modified antisense oligonucleotides directed against Ha‐ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. , 1991, The EMBO journal.

[8]  M. Campiglio,et al.  Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification , 1991, International journal of cancer.

[9]  R. Kumar,et al.  Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells , 1991, Molecular and cellular biology.

[10]  R. Morrison.  Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes. , 1991, The Journal of biological chemistry.

[11]  M. Kraus,et al.  Increased erbB-2 gene copies and expression in multiple stages of breast cancer. , 1990, Cancer research.

[12]  J C Reed,et al.  Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. , 1990, Cancer research.

[13]  L. Neckers,et al.  Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line. , 1990, Cancer research.

[14]  R. Lupu,et al.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.

[15]  Tidd Dm.  A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. , 1990 .

[16]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[17]  G. Plowman,et al.  Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Uhlmann,et al.  Antisense oligonucleotides: a new therapeutic principle , 1990 .

[19]  C. Redmond,et al.  Pathologic findings from the national surgical adjuvant breast and bowel projects (NSABP) prognostic discriminants for 8‐year survival for node‐negative invasive breast cancer patients , 1990, Cancer.

[20]  B. Shiramizu,et al.  Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide , 1990, The Lancet.

[21]  M. J. van de Vijver,et al.  Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies. , 1990, Oncogene.

[22]  V. Prassolov,et al.  Polymorphic changes of cell phenotype caused by elevated expression of an exogenous NEU proto-oncogene. , 1990, Oncogene.

[23]  J. Bacus,et al.  HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. , 1990, Archives of pathology & laboratory medicine.

[24]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. McGuire,et al.  HER-2/neu oncogene protein and prognosis in breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Hélène.  The 1988 Walter Hubert lecture*: Artificial control of gene expression by oligodeoxynucleotides covalently linked to intercalating agents , 1989, British Journal of Cancer.

[27]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[28]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[29]  M. Greene,et al.  The neu (c-erbB-2) oncogene. , 1989, Seminars in oncology.

[30]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[31]  J. Horiguchi,et al.  CSF-1 and C-FMS gene expression in human carcinoma cell lines. , 1988, Biochemical and biophysical research communications.

[32]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[33]  M. Greene,et al.  Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. , 1988, Oncogene.

[34]  E. Wickstrom,et al.  Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Nienhuis,et al.  An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation , 1988, Molecular and cellular biology.

[36]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[38]  M. Kraus,et al.  Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms. , 1987, The EMBO journal.

[39]  R. Weinberg,et al.  Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[40]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[41]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[42]  R. Weinberg,et al.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. , 1985, Science.

[43]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.

[44]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  D. Tidd.  A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. , 1990, Anticancer research.

[46]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[47]  S. Warnaar.  Selection of Monoclonal Antibodies. , 1987 .

[48]  human breast cancer , 2022 .